ラノテプラーゼ (遺伝子組換え) (JAN);
Lanoteplase (USAN/INN);
Lanoteplase (genetical recombination) (JAN)

GARSYQVIDT RATCYEDQGI SYRGTWSTAE SGAECTNWQS SALAQKPYSG RRPDAIRLGL
GNHNYCRNPD RDSKPWCYVF KAGKYSSEFC STPACSEGNS DCYFGNGSAY RGTHSLTESG
ASCLPWNSMI LIGKVYTAQN PSAQALGLGK HNYCRNPDGD AKPWCHMLKN RRLTWEYCDV
PSCSTCGLRQ YSQPQFRIKG GLFADIASHP WQAAIFAKHR RSPGERFLCG GILISSCWIL
SAAHCFQERF PPHHLTVILG RTYRVVPGEE EQKFEVEKYI VHKEFDDDTY DNDIALLQLK
SDSSRCAQES SVVRTVCLPP ADLQLPDWTE CELSGYGKHE ALSPFYSERL KEAHVRLYPS
SRCTSQHLLN RTVTDNMLCA GDTRSGGPQA NLHDACQGDS GGPLVCLNDG RMTLVGIISW
GLGCGQKDVP GVYTKVTNYL DWIRDNMRP
(Disulfide bridge: 14-95, 35-77, 66-90, 102-183, 123-165, 154-178, 186-317, 229-245, 237-306, 331-406, 363-379, 396-424; Glycosylation site: 106, 370)

血栓溶解薬, 組織プラスミノーゲン活性化薬 (t-PA)

遺伝子組換え組織プラスミノーゲン活性化因子 [HSA:5327] [KO:K01343] [EC:3.4.21.68]

DDI search